Real-life Data on the Effect of Medical Therapy for Amiodarone-induced Thyrotoxicosis on CV Events and Hospitalizations

被引:5
作者
Cappellani, Daniele [1 ]
Marconcini, Giulia [1 ]
Manetti, Luca [1 ]
Bartalena, Luigi [2 ]
Bogazzi, Fausto [1 ,3 ]
机构
[1] Univ Pisa, Dept Clin & Expt Med, Unit Endocrinol, I-56124 Pisa, Italy
[2] Univ Insubria, Dept Med & Surg, I-21100 Varese, Italy
[3] Univ Pisa Osped Cisanello, Dept Clin & Expt Med, Unit Endocrinol, Via Paradisa 2, I-56124 Pisa, Italy
关键词
amiodarone-induced thyrotoxicosis; AIT; thyrotoxicosis; cardiovascular events; MACEs; FLOW DOPPLER SONOGRAPHY; CARDIOVASCULAR EVENTS; MANAGEMENT; MORTALITY; HYPERTHYROIDISM; DYSFUNCTION; DIAGNOSIS; DISEASE; GUIDELINES; AMERICAN;
D O I
10.1210/clinem/dgac756
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context Patients with amiodarone-induced thyrotoxicosis (AIT) often receive initial therapy for thyrotoxicosis in several different medical settings before admission to a referral center. Objective This work aimed to determine whether first-line medical therapy (ie, therapies for thyrotoxicosis at first diagnosis of AIT) affects the outcome of AIT patients. Methods A single-center historical-prospective cohort study was conducted on 313 AIT patients. Clinical and biochemical data were collected at first diagnosis, at a referral center, and during the course of AIT. Primary outcomes were cardiovascular (CV) events and hospitalizations. First-line therapies were considered appropriate when they included glucocorticoids for type 2 AIT and methimazole for type 1 AIT at the approved dose, either alone (optimal medical therapy, OMT) or in combination (right-dose combination therapy, RCT). Other therapies were considered not appropriate, including no therapy. Duration of exposure to thyrotoxicosis was the time from first diagnosis of AIT to its remission. Results A total of 34.5% patients received appropriate therapies (28.1% OMT, 6.4% RCT), whereas the remaining (65.5%) received inappropriate therapies. CV events and hospitalizations were more frequent in patients who received inappropriate therapies (33.2% vs 4.5%, and 24.9% vs 6.5%, respectively; P < .0001 for both). Appropriate therapies reduced serum thyroid hormone concentrations (P = .018) from first diagnosis to referral, unlike the inappropriate therapies. The duration of exposure to thyrotoxicosis was longer in patients receiving inappropriate therapies and was a risk factor for arrhythmias (hazard ratio [HR] 1.004; P = .0008), major acute CV events (HR 1.004; P = .020), and hospitalizations (HR 1.006; P < .0001). Conclusion The first medical therapy of AIT influences the exposure time to thyrotoxicosis and the occurrence of CV events and hospitalizations.
引用
收藏
页码:1298 / 1307
页数:10
相关论文
共 42 条
[1]   Diagnosis and management of amiodarone-induced thyrotoxicosis in Europe: results of an international survey among members of the European Thyroid Association [J].
Bartalena, L ;
Wiersinga, WM ;
Tanda, ML ;
Bogazzi, F ;
Piantanida, E ;
Lai, A ;
Martino, E .
CLINICAL ENDOCRINOLOGY, 2004, 61 (04) :494-502
[2]   2018 European Thyroid Association (ETA) Guidelines for the Management of Amiodarone-Associated Thyroid Dysfunction [J].
Bartalena, Luigi ;
Bogazzi, Fausto ;
Chiovato, Luca ;
Hubalewska-Dydejczyk, Alicja ;
Links, Thera P. ;
Vanderpump, Mark .
EUROPEAN THYROID JOURNAL, 2018, 7 (02) :55-66
[3]   Color flow doppler sonography in thyrotoxicosis factitia [J].
Bogazzi, F ;
Bartalena, L ;
Vitti, P ;
Rago, T ;
Brogioni, S ;
Martino, E .
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 1996, 19 (09) :603-606
[4]   Amiodarone and the thyroid: A 2012 update [J].
Bogazzi, F. ;
Tomisti, L. ;
Bartalena, L. ;
Aghini-Lombardi, F. ;
Martino, E. .
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2012, 35 (03) :340-348
[5]   Thyroid color flow doppler sonography and radioiodine uptake in 55 consecutive patients with amiodarone-induced thyrotoxicosis [J].
Bogazzi, F ;
Martino, E ;
Dell'Unto, E ;
Brogioni, S ;
Cosci, C ;
Aghini-Lombardi, F ;
Ceccarelli, C ;
Pinchera, A ;
Bartalena, L ;
Braverman, LE .
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2003, 26 (07) :635-640
[6]   Color flow Doppler sonography rapidly differentiates type I and type II amiodarone-induced thyrotoxicosis [J].
Bogazzi, F ;
Bartalena, L ;
Brogioni, S ;
Mazzeo, S ;
Vitti, P ;
Burelli, A ;
Bartolozzi, C ;
Martino, E .
THYROID, 1997, 7 (04) :541-545
[7]  
Bogazzi F., 2020, THYROID HEART COMPRE, P311
[8]   Glucocorticoid response in amiodarone-induced thyrotoxicosis resulting from destructive thyroiditis is predicted by thyroid volume and serum free thyroid hormone concentrations [J].
Bogazzi, Fausto ;
Bartalena, Luigi ;
Tomisti, Luca ;
Rossi, Giuseppe ;
Tanda, Maria Laura ;
Dell'Unto, Enrica ;
Aghini-Lombardi, Fabrizio ;
Martino, Enio .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2007, 92 (02) :556-562
[9]   Continuation of Amiodarone Delays Restoration of Euthyroidism in Patients with Type 2 Amiodarone-Induced Thyrotoxicosis Treated with Prednisone: A Pilot Study [J].
Bogazzi, Fausto ;
Bartalena, Luigi ;
Tomisti, Luca ;
Rossi, Giuseppe ;
Brogioni, Sandra ;
Martino, Enio .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2011, 96 (11) :3374-3380
[10]   Approach to the Patient with Amiodarone-Induced Thyrotoxicosis [J].
Bogazzi, Fausto ;
Bartalena, Luigi ;
Martino, Enio .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2010, 95 (06) :2529-2535